Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions
The Prostate2008Vol. 68(10), pp. 1116–1125
Citations Over TimeTop 12% of 2008 papers
Nanda K. Thudi, Chelsea K. Martin, Murali V.P. Nadella, Soledad Fernández, Jillian L. Werbeck, Joseph J. Pinzone, Thomas J. Rosol
Abstract
Our results demonstrated that the incidence of prostate cancer bone metastases in vivo was not reduced by zoledronic acid even though zoledronic acid inhibited bone resorption and bone loss associated with the mixed osteoblastic/osteolytic bone metastases in the Ace-1 model.
Related Papers
- → Prevention of Wear Particle-Induced Osteolysis by a Novel V-ATPase Inhibitor Saliphenylhalamide through Inhibition of Osteoclast Bone Resorption(2012)77 cited
- → Review of Cellular Mechanisms of Tumor Osteolysis(2000)65 cited
- → Bulleyaconitine A prevents Ti particle‐induced osteolysis via suppressing NF‐κB signal pathway during osteoclastogenesis and osteoblastogenesis(2018)15 cited
- The clinical significance of serum NTx and BSP treated by zoledronic acid for bone metastasis of lung cancer(2011)
- [A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].(2011)